Leerink Partnrs Issues Pessimistic Outlook for ELAN Earnings

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Equities researchers at Leerink Partnrs decreased their Q1 2025 earnings per share estimates for Elanco Animal Health in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $0.29 for the quarter, down from their prior forecast of $0.32. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.80 EPS, FY2027 earnings at $1.16 EPS and FY2028 earnings at $1.37 EPS.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.08 EPS.

Other analysts also recently issued reports about the stock. Stifel Nicolaus lowered their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, February 21st. Barclays dropped their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday. Leerink Partners assumed coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price target on the stock. UBS Group lowered their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Morgan Stanley cut their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $15.83.

Elanco Animal Health Trading Up 2.4 %

Shares of ELAN traded up $0.27 during mid-day trading on Thursday, reaching $11.19. The company's stock had a trading volume of 6,898,446 shares, compared to its average volume of 4,959,782. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80. The stock has a market cap of $5.53 billion, a PE ratio of 27.96, a P/E/G ratio of 2.50 and a beta of 1.42. The company's fifty day moving average price is $11.72 and its two-hundred day moving average price is $13.05. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Institutional Trading of Elanco Animal Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its holdings in Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after purchasing an additional 37,022,891 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Elanco Animal Health by 76.6% in the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company's stock worth $147,747,000 after buying an additional 4,361,799 shares in the last quarter. Norges Bank purchased a new stake in Elanco Animal Health in the fourth quarter worth about $47,424,000. Brandes Investment Partners LP boosted its position in Elanco Animal Health by 66.9% during the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company's stock valued at $69,405,000 after acquiring an additional 2,296,691 shares in the last quarter. Finally, Freestone Grove Partners LP bought a new position in shares of Elanco Animal Health in the 4th quarter worth approximately $20,396,000. Hedge funds and other institutional investors own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.